IL32 and breast cancer: Moreover, this inhibitory effect of IL-32θ was addressed in breast cancer as well, as it suppresses the binding of CCL18, a chemotactic cytokine involved in the several cancer pathogenesis and progression and associated with poor prognosis (68–70), to its receptor and therefore inhibited the further cascade of activation/phosphorylation of STAT3 (44).